Lipogems Completes ARISE I Clinical Trial Phase for Knee OA
Lipogems is excited to share that it has reached an important landmark in its ongoing clinical journey. The ARISE I trial's final patient visit was successfully completed, indicating a new chapter in the fight against knee osteoarthritis (OA). This advancement is especially vital for those individuals who are not yet prepared for surgery or do not qualify for knee replacement procedures.
Understanding the ARISE I Trial Results
The ARISE I trial is a double-blinded, randomized controlled study involving 173 participants from 18 esteemed sites across the U.S. Its primary focus is on evaluating pain relief and functional improvement in patients at the one-year mark post-treatment. Excitingly, the results detailing the trial’s efficacy and safety are anticipated to be released by the end of 2025, which will shed light on Lipogems' unique approach to treating knee osteoarthritis.
Leadership Remarks on Trial Achievement
Carl Llewellyn, Chief Executive Officer of Lipogems, expressed his enthusiasm: "We are thrilled to reach this significant milestone. This accomplishment brings us one step closer to making Lipogems a mainstream treatment option for patients with knee osteoarthritis that have historically had limited options. The successful conclusion of this trial represents the hard work and dedication of our team and the clinical sites, as well as the trust placed in us by the patients."
The Importance of Lipogems Technology
For over a decade, the Lipogems device has been cleared by the FDA for general use in orthopaedics and arthroscopic surgeries. However, the ARISE studies represent an important milestone, as they constitute the largest clinical trials the company has conducted to date. Both the ARISE I and II trials are crucial in obtaining a specific indication for treating knee OA.
Analyzing Safety and Efficacy
Research is being conducted to analyze the data collected during the trials, focusing on how patients with mild to moderate knee OA benefit from Lipogems therapy. This study aims to demonstrate whether Lipogems can significantly enhance pain management and functional mobility for these patients, addressing a major need in the orthopedic community.
Commitment to Accessibility
Lipogems is dedicated to increasing patient access to its innovative technology. The company recognizes the growing demand for less invasive treatment options that support natural healing and recovery. Securing proper reimbursement will be key in making these advancements more widely available, ultimately enhancing patient outcomes.
About Lipogems International
Lipogems International stands as a pioneering privately held medical device organization dedicated to utilizing adipose tissue solutions to restore and maintain patient quality of life and recovery timelines. With products designed for various medical specialties, including orthopaedics, Lipogems is actively exploring new applications to expand its reach. The company is proud to operate in 29 countries, firmly committed to helping patients regain their active lifestyles through innovative treatment solutions and scientific excellence.
Frequently Asked Questions
What is the ARISE I trial about?
The ARISE I trial investigates the effectiveness of Lipogems for treating knee osteoarthritis among patients not suitable for knee replacement.
How many participants were enrolled in the trial?
The trial enrolled 173 participants from accredited sites across the United States.
When are the results expected to be released?
Results detailing the trial's efficacy will be announced by the end of 2025.
Who leads the efforts at Lipogems?
Carl Llewellyn serves as the Chief Executive Officer, guiding the company's strategic initiatives.
Where is Lipogems technology available?
Lipogems products are available in 29 countries worldwide, focusing on improving the lives of patients globally.
